ribosomal protein L23Genealiases: L23 · rpL17 · uL14
Q-omics provides the consensus-scored RPL23 profile across patient tissues and cancer cell-line models. RPL23 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPL23 is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, RPL23 protein abundance shows 35,537 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, KIRC, and HNSC as cancer lineages where RPL23 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL23 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL23 survival associations across molecular data types. RPL23 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (3) and mass-spec protein abundance (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL23 RNA expression–survival associations across cancer types. High RPL23 expression shows unfavorable associations in LIHC, ACC, KIRP, HNSC and SCLC, but favorable associations in UVM. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPL23 RNA expression.
This table summarizes RPL23 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 10. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for RPL23. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL23 shows lower tumor expression in KICH and higher tumor expression in KIRC, KIRP, LIHC, COAD and CHOL. The KIRC box plot shows higher RPL23 RNA expression in tumor versus normal tissue (log2 FC = +0.782, t-test p < 0.001).
This table shows molecular features associated with RPL23 in patient tissues and cancer cell lines. In patient samples, RPL23 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, RPL23 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and CNS.
